Emphasis on neoadjuvant therapy for “resectable” pancreatic cancer

• Main Author: LIU Chang
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2015-05-01
• Series: Linchuang Gandanbing Zazhi
• Subjects: pancreatic neoplasms; neoadjuvant therapy; editorial
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=6483&ClassID=41585614

The treatment concept for pancreatic cancer is being transferred from “surgery first” to MDT model. The postoperative adjuvant treatment of pancreatic cancer can significantly improve the prognosis of patients and has become the standardized diagnostic and treatment practice; the value and significance of neoadjuvant therapy remains unclear. Limited clinical studies of “borderline resectable” pancreatic cancer have shown that neoadjuvant therapy can improve the R0 resection rate and improve the prognosis of patients, and it is recommended for clinical application. But the significance of neoadjuvant therapy in “resectable” pancreatic cancer is still controversial. There is a lack of consensus on indications, cycles, and regimens. It is necessary to carry out a series of prospective control studies to objectively evaluate the value of neoadjuvant therapy in improving the prognosis of “resectable” pancreatic cancer.